Condition: Glioblastoma · Sponsor: University of Zurich
The goal of this 1:1 randomized, multi-center, open-label phase Ib/II clinical trial is to explore the efficacy of the add-on of the anti-glutamatergic drugs gabapentin, sulfasalazine and memantine to standard chemoradiotherapy with temozolomide compared to chemoradiotherapy alone in patients with newly diagnosed glioblastoma.
This description comes directly from the study's public registry record.
Hans-Georg Wirsching, MD · +41432532928 · hans-georg.wirsching@usz.ch
Michael Weller, MD · +41442555513 · michael.weller@usz.ch
Always discuss trial participation with your own doctor first.
| University Hospital Zurich | Zurich, Canton of Zurich, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05664464